BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 16 stocks Jim Cramer recently discussed. When a caller asked about the company during the lightning round, Cramer remarked:
“You know what, BioMarin, I am getting tired of the orphan drug model. I just… [don’t] think that it’s working. I think it worked for some time. I don’t think it works now.”
A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide.
BioMarin (NASDAQ:BMRN) is a biotechnology company focused on turning genetic research into treatments that significantly improve patients’ lives, supported by a history of innovation and a growing pipeline of therapies. It is worth noting that in 2023, when Cramer was asked about the company during a lightning round, he commented, “I would hold onto that one.” Since the comment was aired back in January 2023, BMRN stock has gone down more than 49%.
While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
finance.yahoo.com
#Dont #Works
